UPDATE 1-U.S. allows Actavis Plc's purchase of Forest Labs with conditions
(Adds details of drugs to be divested, share price, other pharma deals)
WASHINGTON, June 30 (Reuters) - Generic drugmaker Actavis Plc has won U.S. approval to buy specialty pharmaceuticals company Forest Laboratories on condition it sell or relinquish the rights to four generic medicines, the Federal Trade Commission said on Monday.
The deal was valued at about $25 billion when it was announced in February.
The companies have agreed to relinquish their right to diltiazem hydrochloride extended release capsules, which are used to treat hypertension and some anginas.
They also agreed to sell three medicines - ursodiol tablets used to treat cirrhosis of the liver, propranolol hydrochloride extended release capsules used to treat hypertension, and lamotrigine orally disintegrating tablets used to prevent seizures.
Shareholders of both companies have already approved the proposed transaction.
Dublin-based Actavis, whose biggest competitors include Teva Pharmaceuticals Industries and Mylan, has recently been acquiring specialty branded drug makers to boost profit margins and sales.
Forest, which acquired privately held drugmaker Aptalis in January for $2.9 billion, faces a patent cliff on several of its biggest drugs, including Alzheimer's treatment Namenda. It recently won antitrust approval to buy Furiex Pharmaceuticals Inc in a transaction worth about $1.46 billion.
- Boeing, SpaceX win contracts to build 'space taxis' for NASA
- Wildfire rips through 150 homes in Northern California
- Polls show Scottish opponents of independence with slight lead ahead of vote |
- Fed could hint on rate-hike plans as it prepares for policy turn
- iPhone comes out of a 'bygone era', reviewers hail bigger handset